Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2666-2674

  Kiviharju, Taija M ^a   Lecane, Philip S ^a,b   Sellers, Robert G ^a   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA GALACTOSIDASE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DITERPENE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PHENANTHRENE DERIVATIVE; PROTEIN MDM2; PROTEIN P53; TRIPTOLIDE; NATURAL PRODUCT; PROTEIN BCL 2; PROTEIN P21; TRIPTERYGIUM WILFORDII EXTRACT; TRIPTOLIDE SUCCINATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CLINICAL TRIAL; CYTOLOGY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; EPITHELIUM CELL; HUMAN; IMMUNOBLOTTING; MALE; METABOLISM; PHENOTYPE; PROSTATE; SIGNAL TRANSDUCTION; TIME; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN CELL; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN CONTENT; SENESCENCE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BETA-GALACTOSIDASE; CELL CYCLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPITHELIAL CELLS; HUMANS; IMMUNOBLOTTING; MALE; NUCLEAR PROTEINS; PHENANTHRENES; PHENOTYPE; PROSTATE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; HUMAN; PROTEIN P53; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0036023433     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Traditional Chinese medicines as immunosuppressive agents
2. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii
3. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii
4. Inhibitory effect of triptolide on colony formation of breast and stomach cancer cell lines
5. PG490 (triptolide) cooperates with tumor necrosis factor-α to induce apoptosis in tumor cells
6. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway
7. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis
8. Antiinflammatory effects of triptolide in human bronchial epithelial cells
9. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-ΚB transcriptional activation
10. WAF1, a potential mediator of p53 tumor suppression
11. Roles for p53 in growth arrest and apoptosis: Putting on the brakes after genotoxic stress
12. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
13. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents
14. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
15. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-κB activation in gastric cancer cells
16. An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer
17. Culture of human prostatic epithelial cells
18. Epithelial cell culture: Prostate
19. Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH)
20. 3-induced growth inhibition
21. Retinol metabolism and lecithin retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens
22. Clonal growth of normal human epidermal keratinocytes in a defined medium
23. Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation
24. A biomarker that identifies senescent human cells in culture and in aging skin in vivo
25. Mapping of the p53 and mdm-2 interaction domains
26. Cancer statistics, 2001
27. Chemotherapy for prostate cancer
28. Epigenetic aspects of cellular senescence
29. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents
30. INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells
31. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells
32. The cat and mouse games that genes, viruses, and cells play
33. Regulation of p53 downstream genes
34. Mdm2 promotes the rapid degradation of p53
35. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
36. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis
37. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases
38. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis
39. 1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage
40. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells
41. The complexity of p53 modulation: Emerging patterns from divergent signals
42. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
43. Negative regulation of bcl-2 expression by p53 in hematopoietic cells
44. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells
45. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
46. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade
47. p53 oncogene mutations in three human prostate cancer cell lines
48. PG490-88 exerts potent anticancer activity alone and in combination therapy in a nude mouse xenograft model
49. From the cover: P53 accumulates but is functionally impaired when DNA synthesis is blocked
50. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together
51. 2 response of normal human fibroblasts